Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-10-29
85
Participants Needed
26
Research Sites
N/A
Total Duration
On this page
AI-Summary
Official Title
Who Can Participate
Trial Site Locations
How is the study designed?
Frequently Asked Questions
Research Publications
AI-Summary
What this Trial Is About
The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection.
HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC.
CONDITIONS
Official Title
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Inclusion Criteria
You may be eligible for this study if you:
Are HIV-positive.
Have a CD4 count under 50 cells/mm3 or between 100 and 250 cells/mm3 within 30 days of study entry.
Have at least one symptom (e.g., fever, diarrhea, or weight loss) suggestive of MAC infection.
Have MAC infection with 7 days or less of MAC treatment.
Have an HIV blood level greater than 10,000 copies/ml within 30 days of study entry.
Are 18 years of age or older.
Exclusion Criteria
You will not be eligible for this study if you:
Have any active infection (except for MAC in Group 2 patients) or any cancer.
Are unable to follow an acceptable anti-HIV drug regimen (Groups 2 and 3).
Are pregnant or breast-feeding.
You will not qualify if you...
History of severe allergic reactions to study medication
Currently pregnant or breastfeeding
Recent participation in another clinical trial within the last 30 days
Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 26 locations
1
Univ of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Status Unknown
2
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, United States, 900331079
Status Unknown
3
Univ of California / San Diego Treatment Ctr
San Diego, California, United States, 921036325
Status Unknown
4
Stanford Univ Med Ctr
Stanford, California, United States, 943055107
Status Unknown
5
Howard Univ
Washington D.C., District of Columbia, United States, 20059
Status Unknown
6
Univ of Miami School of Medicine
Miami, Florida, United States, 331361013
Status Unknown
7
Emory Univ
Atlanta, Georgia, United States, 30308
Status Unknown
8
Northwestern Univ Med School
Chicago, Illinois, United States, 60611
Status Unknown
9
Cook County Hosp
Chicago, Illinois, United States, 60612
Status Unknown
10
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, United States, 60612
Status Unknown
11
Indiana Univ Hosp
Indianapolis, Indiana, United States, 462025250
Status Unknown
12
Division of Inf Diseases/ Indiana Univ Hosp
Indianapolis, Indiana, United States, 46202
Status Unknown
13
SUNY / Erie County Med Ctr at Buffalo
Buffalo, New York, United States, 14215
Status Unknown
14
Beth Israel Med Ctr
New York, New York, United States, 10003
Status Unknown
15
Bellevue Hosp / New York Univ Med Ctr
New York, New York, United States, 10016
Status Unknown
16
St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr
New York, New York, United States, 10021
Status Unknown
17
Univ of Rochester Medical Center
Rochester, New York, United States, 14642
Status Unknown
18
Univ of Cincinnati
Cincinnati, Ohio, United States, 452670405
Status Unknown
19
Case Western Reserve Univ
Cleveland, Ohio, United States, 44106
Status Unknown
20
Ohio State Univ Hosp Clinic
Columbus, Ohio, United States, 432101228
Status Unknown
21
Univ of Pennsylvania at Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Status Unknown
22
Julio Arroyo
West Columbia, South Carolina, United States, 29169
Status Unknown
23
Univ of Texas Southwestern Med Ctr of Dallas
Dallas, Texas, United States, 75235
Status Unknown
24
Univ of Texas, Southwestern Med Ctr of Dallas
Dallas, Texas, United States, 75390
Status Unknown
25
Univ of Texas Galveston
Galveston, Texas, United States, 775550435
Status Unknown
26
Univ of Washington
Seattle, Washington, United States, 98104
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study.
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections | DecenTrialz